Home  /  Resource Library  /  IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real world experience in the modern era

IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real world experience in the modern era

Results of a study investigating rituximab based chemoimmunotherapy for treatment of aggressive relapsed B-cell lymphomas.